Caldwell Sutter Capital’s BridgeBio Pharma BBIO Stock Holding History

Caldwell Sutter Capital’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$149K	Hold	2,000	–	–	0.06%	254
2026 Q1	$149K	Hold	2,000	–	–	0.06%	251
2025 Q4	$153K	Hold	2,000	–	–	0.06%	244
2025 Q3	$104K	Sell	2,000 -200	-9%	-$9.76K	0.04%	280
2025 Q2	$95K	Hold	2,200	–	–	0.04%	287
2025 Q1	$76.1K	Hold	2,200	–	–	0.04%	307
2024 Q4	$60.4K	Hold	2,200	–	–	0.03%	332
2024 Q3	$56K	Hold	2,200	–	–	0.03%	342
2024 Q2	$55.7K	Hold	2,200	–	–	0.03%	339
2024 Q1	$68K	Sell	2,200 -1,000	-31%	-$34K	0.03%	316
2023 Q4	$129K	Hold	3,200	–	–	0.07%	239
2023 Q3	$84.4K	Hold	3,200	–	–	0.05%	274
2023 Q2	$55K	Buy	+3,200	New	+$48.1K	0.03%	313

Other funds holding BBIO

Jupiter Topco New York $245B AUM

KKRC

Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

ACM

Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Caldwell Sutter Capital's BBIO Position: Q2 2026 in Review

Caldwell Sutter Capital held its BridgeBio Pharma (BBIO) position steady in Q2 2026 at 2,000 shares worth $149K. The position accounts for 0.06% of the portfolio, ranked #254.

Caldwell Sutter Capital first reported a position in BBIO in Q2 2023 and has held it in 13 quarters since. The position peaked at $153K in Q4 2025. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

Caldwell Sutter Capital held 2,000 shares of BridgeBio Pharma worth $149K as of Q2 2026.
Caldwell Sutter Capital left its BridgeBio Pharma share count unchanged in Q2 2026.
BridgeBio Pharma made up 0.06% of Caldwell Sutter Capital's portfolio in Q2 2026, its #254 holding.
Caldwell Sutter Capital first reported a position in BridgeBio Pharma in Q2 2023 and has held it in 13 quarters since.
Caldwell Sutter Capital's BridgeBio Pharma position peaked at $153K in Q4 2025.
474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Caldwell Sutter Capital's 13F filing for Q2 2026, filed 5 Aug 2026.